CancerNetwork® spoke with Rafael Fonseca, MD, about real-world use of daratumumab-containing regimens as either frontline or second-line therapy for transplant-ineligible multiple myeloma.
At the 63rd American Society of Hematology Annual Meeting & Exposition, CancerNetwork® sat down with Rafael Fonseca, MD, director of Innovation and Transformational Relationships at the Mayo Clinic in Phoenix, Arizona, to talk about an abstract that he presented on the use of daratumumab-containing regimens in patients with transplant-ineligible multiple myeloma. He said that standard practice regarding use of daratumumab in the front- or later-line settings may vary depending on the treatment facility.
In the United States, both the use of RVd [lenalidomide, bortezomib, and dexamethasone] as well as the MAIA trial [NCT02252172] regimen [daratumumab (Darzalex) plus lenalidomide and dexamethasone (D-Rd)] are accepted as standard of care. What I have perceived is that within the academic centers, more and more people are using the MAIA regimen. Part of this relates to the fact that the data for superiority are there, as well as a perceived superiority. That’s why we’re doing this modeling.
However, when one looks at the community practices, RVd still has a very strong hold on those prescribing patterns. This is probably related to the familiarity that our colleagues in the community have with a regimen like RVd, which has been used extensively. But over time, we’ve seen more and more patients being treated with a MAIA-type combination.
Fonesca R, Facon T, Hashim M, et al. First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios. Presented at the 2021 American Society of Hematology Annual Congress. December 11-14, 2021. Virtual. Abstract 118. https://bit.ly/3pLLttF